TD Cowen维持Agios Pharmaceuticals(AGIO.US)买入评级
agios pharmaceuticals分析师评级
丰业银行维持Agios Pharmaceuticals(AGIO.US)买入评级,维持目标价75美元
RBC将Agios Pharmaceuticals的目标价从55美元上调至57美元,并维持其“跑赢大盘”评级。
agios pharmaceuticals被Scotiabank维持在板块表现评级
agios pharmaceuticals分析师评级
丰业银行维持Agios Pharmaceuticals(AGIO.US)买入评级,上调目标价至75美元
TD Cowen维持Agios Pharmaceuticals(AGIO.US)买入评级
Leerink Partners维持Agios Pharmaceuticals(AGIO.US)持有评级
agios pharmaceuticals被Scotiabank维持在板块表现优异
美银证券维持Agios Pharmaceuticals(AGIO.US)买入评级
丰业银行维持Agios Pharmaceuticals(AGIO.US)买入评级,上调目标价至53美元
加皇资本市场维持Agios Pharmaceuticals(AGIO.US)买入评级,维持目标价55美元
TD Cowen维持Agios Pharmaceuticals(AGIO.US)买入评级
派杰投资维持Agios Pharmaceuticals(AGIO.US)买入评级,维持目标价56美元
Scotiabank宣布agios pharmaceuticals股票的目标价格为51.00美元/股。
Leerink Partners维持Agios Pharmaceuticals(AGIO.US)持有评级
瑞杰金融上调Agios Pharmaceuticals(AGIO.US)至买入评级,目标价51美元
agios pharmaceuticals分析师评级
林宏富公司在Raymond James获得表现外行评级